Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $107.33

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $107.3333.

Several research firms have commented on ANIP. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 4,772 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares in the company, valued at approximately $2,901,264.30. This represents a 10.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Stephen P. Carey sold 7,312 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $75.50, for a total transaction of $552,056.00. Following the completion of the transaction, the chief financial officer owned 185,543 shares of the company’s stock, valued at approximately $14,008,496.50. This trade represents a 3.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 100,564 shares of company stock valued at $7,800,862. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. KBC Group NV acquired a new position in shares of ANI Pharmaceuticals in the first quarter worth about $28,000. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter worth about $28,000. Hantz Financial Services Inc. raised its position in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares during the period. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter worth about $48,000. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth about $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $78.01 on Monday. ANI Pharmaceuticals has a one year low of $56.71 and a one year high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 19.75 and a beta of 0.46. The firm’s fifty day moving average is $77.29 and its two-hundred day moving average is $80.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the prior year, the company earned $1.70 earnings per share. The firm’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts expect that ANI Pharmaceuticals will post 7.73 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.